Compare Pfizer Inc (PFE) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs TJX Companies Inc — how do they compare? Pfizer Inc trades at $24.9 (market cap $142.14B), while TJX Companies Inc trades at $156.69 (market cap $171.28B). The key difference: TJX Companies Inc is the larger of the two by market cap, and Pfizer Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| PFE | TJX | |
|---|---|---|
Market Cap | $142.14B | $171.28B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $28.56 | $168.41 |
52-Week Low | $23.29 | $124.53 |
Enterprise Value | $192.80B | $179.88B |
Dividend Yield | 6.9% | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
TJX trades at $155.00, up 0.4% on the day, with a bullish technical outlook supported by moving averages and strong fundamental performance. The company reported revenue of $56.36 billion in 2025 with a net income margin of 9.4%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights TJX as a beneficiary of shifting retail trends and economic uncertainty.
The outlook for TJX remains positive, driven by earnings growth, international expansion, and strong analyst support with a consensus price target of $181.80. Key risks include competitive pressures in discount retail and sensitivity to consumer spending fluctuations, but the company's robust cash flow and dividend payments provide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
